Skip to Content
Søg Menu
We cover

ASCO GU | Genitourinary Cancers Symposium

ASCO GU 2026

ASCO GU 2026: Adjuvant Belzutifan + Pembrolizumab Reduces Risk of Recurrence or Death in ccRCC

  • / Jan Andreasen

Martin Zarba

RWD for mRCC: Cabozantinib + Nivolumab Shows Comparable Results to CheckMate 9ER

/ Martin Zarba
ASCOGU26Nyrecancer Play the Video
Fernando De Moura

ASCO GU 2026: Intensifying Neoadjuvant Androgen Blockade Before Prostatectomy in High-Risk Prostate Cancer

/ Fernando de Moura
ASCOGU26Prostatacancer Play the Video

ASCO GU 2025

Neeraj Agarwal

Talazoparib and Enzalutamide: A Game-Changer for mCRPC

/ Neeraj Agarwal
ASCOGU25Prostatacancer Play the Video

Real-World Treatment Patterns of Nivolumab + Cabozantinib Compared with Other 1L IO Combinations in mRCC

/ Cherrishe Brown-Bickerstaff / Jan Andreasen
ASCOGU25Nyrecancer
Dag Stormoen

Immunterapi og antibody-drug conjugates vil få en central plads i fremtidens behandling af blærecancer

/ Dag Rune Stormoen
ASCOGU25Blærecancer Play the Video
Thomas Powles

Bladder Cancer Treatment Advancements: Key Findings and Progress

/ Thomas Powles
ASCOGU25Blærecancer Play the Video

Bone Pain as a Key Prognostic Indicator in Castration-Sensitive Prostate Cancer

/ Deniz Tural / Jan Andreasen
ASCOGU25Prostatacancer

Real-Life Data Confirms Avelumab Maintenance Benefits in Metastatic Urothelial Carcinoma

/ Deniz Tural / Jan Andreasen
ASCOGU25Blærecancer
Hent flere

Abstracts fra ASCO GU 2024

ASCO GU 2024: CheckMate 914 Trial – Adjuvant Nivolumab Monotherapy vs Placebo for Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy

/ Onkologi / Sofie Pohl

ASCO GU 2024: A Combination of Cabozantinib and Atezolizumab is Promising for Advanced Prostate Cancer Patients with Poor Prognoses

/ Onkologi / Sofie Pohl

ASCO GU 2024: Updated Results from AVENANCE – Real-World Effectiveness of Avelumab in Patients with Advanced Urothelial Carcinoma

/ Onkologi / Sofie Pohl

The 2024 ASCO Genitourinary Cancers Symposium Will Be Covered by BestPractice Nordic

/ Onkologi / Sofie Pohl

The 2024 ASCO Genitourinary Cancers Symposium Will Be Covered by BestPractice Nordic

/ Sofie Pohl
ASCOGU24Gynækologisk cancer

MEDtalks fra ASCO GU 2024

Marc Eid og Karl Semaan

Cancer Epigenomics Improve the Overall Survival and the Quality of Life

/ Marc Eid / Karl Semaan
ASCOGU24Prostatacancer Play the Video
Wadih Issa

Comparing Downstaging in RCC-Patients with Tumor or Without Tumor Thrombus Receiving Neoadjuvant ICI Regimen

/ Wadih Issa
ASCOGU24Nyrecancer Play the Video
Eddy Saad

Understanding Mechanisms Behind Acquired Resistance to Immunotherapy in Metastatic Renal Cell Carcinoma

/ Eddy Saad
ASCOGU24Nyrecancer Play the Video
Renee Maria Saliby

The Potential for Intermediate Clinical Endpoints as Surrogates for Overall Survival

/ Renee Maria Saliby
ASCOGU24Nyrecancer Play the Video
Jakob Lauritsen

Highlights fra ASCO GU 2024 om prostatacancer i en dansk kontekst

/ Jakob Lauritsen
ASCOGU24Prostatacancer Play the Video
Philipp Ivanyi

Real-World Evidence on Lenvatinib plus Everolimus in Patients with Pre-Treated Advanced Renal Cell Carcinoma

/ Philipp Ivanyi
ASCOGU24Nyrecancer Play the Video
Ahmed Rehan

Real-World Data on Maintenance Avelumab Treatment

/ Ahmed Rehan
ASCOGU24Blærecancer Play the Video
Dag Rune Stormoen

Highlights fra ASCO GU 2024 om blærekræft i en dansk kontekst

/ Dag Rune Stormoen
ASCOGU24Blærecancer Play the Video
Petros Grivas

Long-Term Patient-Reported Outcomes Data from the JAVELIN Bladder 100 Trial in Patients with Advanced Urothelial Carcinoma

/ Petros Grivas
ASCOGU24Blærecancer Play the Video
Andrea Apolo

Results from Study of Pembrolizumab in Muscle-Invasive and Locally Advanced Urothelial Carcinoma

/ Andrea Apolo
ASCOGU24Blærecancer Play the Video
Hent flere

Gå ikke glip af det nyeste fra Onkologi

Skriv dig på og modtag nye artikler, MEDtalks, MEDcast, faglige test og magasiner

Send mig seneste nyt fra onkologi

2023

Neal Shore

A Long-Term Benefit of Darolutamide for Patients with nmCRPC

/ Neal Shore
ASCOGU23Prostatacancer Play the Video
Daniel Petrylak

Enfortumab Vedotin as Neoadjuvant Treatment for MIBC

/ Daniel Petrylak
ASCOGU23Blærecancer Play the Video
Ahmed Zedan

Inverse Correlation between Natural Killer Cell and Treatment with Enzalutamide

/ Ahmed H. Zedan
ASCOGU23Prostatacancer Play the Video
Simon Crabb

CAPItello-280 Trial Aims to Confirm Findings from ProCAID Trial

/ Simon Crabb
ASCOGU23Prostatacancer Play the Video
Aristotle Bamias

IMvigor130: Final overall survival (OS) analysis of atezolizumab with/without chemotherapy

/ Aristotle Bamias
ASCOGU23 Play the Video

New Improvement of PFS in First-Line Treatment of Advanced Renal-Cell Carcinoma

/ BestPractice Nordic
ASCOGU23Nyrecancer
Hent flere

ASCO GU 2022

Bone mineral density in patients with castration-sensitive prostate cancer treated with abiraterone

/ Guilhem Roubaud
ASCOGU22Prostatacancer Play the Video
Kim Nguyen Chi

New potential first-line therapy for patients with mCR-prostate cancer and HRR-alterations

/ Kim Nguyen Chi
ASCOGU22Prostatacancer Play the Video
Redas Trepiakas

CYCLONE 2: Abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer

/ Redas Trepiakas
ASCOGU22Prostatacancer Play the Video
Daniel P. Petrylak

Promising neoadjuvant antitumor activity for patients with muscle-invasive bladder cancer

/ Daniel P. Petrylak
ASCOGU22Blærecancer Play the Video

Novel intra-vesical drug delivery system, TAR-200, to be assessed in patients with high-risk non-muscle-invasive bladder cancer

/ BestPractice Nordic
ASCOGU22Blærecancer
Simon Crabb

Maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma

/ Simon Crabb
ASCOGU22Blærecancer Play the Video

Nyt studie med dansk deltagelse tester abemaciclib til patienter med metastatisk mCRPC

/ BestPractice Nordic
ASCOGU22Prostatacancer

Deep PSA declines with apalutamide is associated with lower risk for worsened QoL

/ BestPractice Nordic
ASCOGU22Prostatacancer
Fred Saad

Significant effect of PARP-inhibitor olaparib plus abiraterone in patients with mCRPC

/ Fred Saad
ASCOGU22Prostatacancer Play the Video
Hent flere

Se tidligere dækning

Differentiering af patienter med prostatacancer i forhold til respons

/ Mads Daugaard
ProstatacancerASCO GU21 Play the Video

Nyt studie ændrer den fremtidige behandling af prostatacancer

/ Mads Daugaard
ProstatacancerASCO GU21 Play the Video

Management of Erdafitinib, a pan-FGFR kinase inhibitor, treatment-emergent adverse events

/ Arlene O. Siefker-Radtke
BlærecancerASCO GU21 Play the Video

Patient-reported outcomes of patients with advanced renal cell carcinoma treated with first-line nivolumab plus cabozantinib

/ David Cella
NyrecancerASCO GU21 Play the Video
Flere
Back to top